Showing 341-360 of 371 for: Cochrane Systematic Reviews > Oncology 
- Systemic therapy for treating locoregional recurrence in women with breast cancer
Cochrane Systematic Reviews, 23-Oct-2001
Between 10% and 35% of women with operable breast cancer will experience an isolated locoregional recurrence following their primary treatment. There is currently no good evidence that adjuvant systemic treatment is effective in this situation and there i
- Systemic treatments for metastatic cutaneous melanoma
Cochrane Systematic Reviews, 7-Feb-2018
Systemic therapies for metastatic cutaneous melanoma, the most aggressive of all skin cancers, remain disappointing. Few lasting remissions are achieved and the therapeutic aim remains one of palliation.
- Tamoxifen for early breast cancer
Cochrane Systematic Reviews, 5-Aug-2008
There have been many randomised trials of adjuvant tamoxifen among women with early breast cancer, and an updated overview of their results is presented.
- Tamoxifen for hepatocellular carcinoma
Cochrane Systematic Reviews, 3-Aug-2020
- Tamoxifen for relapse of ovarian cancer
Cochrane Systematic Reviews, 17-Mar-2010
Tamoxifen is an important drug for treating breast cancer. Ovarian cancer cells are known to possess receptors for hormones and may thus also respond to tamoxifen.
- Targeted therapy for advanced renal cell carcinoma
Cochrane Systematic Reviews, 7-Nov-2011
Advanced renal cell carcinoma has been resistant to drug therapy of different types and new types of drug therapy are needed. Targeted agents inhibit known molecular pathways and have been tested in renal cancer for just over a decade.
- Taxane‐containing regimens for metastatic breast cancer
Cochrane Systematic Reviews, 10-Jun-2015
It is generally accepted that taxanes are among the most active chemotherapy agents in the management of metastatic breast cancer. This is an update of a Cochrane review first published in 2003.
- Taxanes for adjuvant treatment of early breast cancer
Cochrane Systematic Reviews, 2-Sep-2019
Adjuvant chemotherapy improves survival in premenopausal and postmenopausal women with early breast cancer. Taxanes are highly active chemotherapy agents used in metastatic breast cancer. Review authors examined their role in early breast cancer. This rev
- Thalidomide for managing cancer cachexia
Cochrane Systematic Reviews, 18-Apr-2012
This is an update of the orginal Cochrane review published on the 18th April 2012. Cancer cachexia is a multidimensional syndrome characterised by wasting, loss of weight, loss of appetite, metabolic alterations, fatigue and reduced performance status. A
- Therapeutic interventions for Burkitt lymphoma in children
Cochrane Systematic Reviews, 6-Jul-2011
Burkitt lymphoma (BL) is an important cancer found mostly in children but uncertainty remains as to the most effective form of management. In endemic areas, late-stage presentation as a result of delayed access to treatment compounds the situation.
- Thymic peptides for treatment of cancer patients
Cochrane Systematic Reviews, 16-Feb-2011
Purified thymus extracts (pTE) and synthetic thymic peptides (sTP) are thought to enhance the immune system of cancer patients in order to fight the growth of tumour cells and to resist infections due to immunosuppression induced by the disease and antine
- Topical agents and dressings for fungating wounds
Cochrane Systematic Reviews, 15-May-2014
Fungating wounds arise from primary, secondary or recurrent malignant disease and are associated with advanced cancer. A small proportion of patients may achieve healing following surgical excision, but treatment is usually palliative. Fungating wound man
- Topotecan for ovarian cancer
Cochrane Systematic Reviews, 16-Apr-2008
Chemotherapeutic agents such as topotecan can be used as salvage treatment in epithelial ovarian carcinoma (EOC). The effects of using topotecan as a therapeutic agent have not been previously been systematically reviewed.
- Toremifene versus tamoxifen for advanced breast cancer
Cochrane Systematic Reviews, 11-Jul-2012
Toremifene (TOR) and tamoxifen (TAM) can both be used as treatments for advanced breast cancer.
- Total versus subtotal hysterectomy for benign gynaecological conditions
Cochrane Systematic Reviews, 18-Apr-2012
Hysterectomy using an abdominal approach removes either the uterus alone (subtotal hysterectomy) or both the uterus and the cervix (total hysterectomy). The latter is more common but the outcomes have not been systematically compared.
- Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma
Cochrane Systematic Reviews, 8-Jun-2012
Hepatocellular carcinoma (HCC) results in more than 600,000 deaths per year. Transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) have become standard loco-regional treatments for unresectable HCC.
- Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
Cochrane Systematic Reviews, 28-Jun-2021
Transurethral resection of the prostate (TURP) has been the gold-standard treatment for alleviating urinary symptoms and improving urinary flow in men with symptomatic benign prostatic hyperplasia (BPH). However, the morbidity of TURP approaches 20%, and
- Trastuzumab containing regimens for early breast cancer
Cochrane Systematic Reviews, 18-Apr-2012
Approximately one-fifth of women who develop early breast cancer have HER2-positive tumours, which if untreated, have a worse prognosis than HER2-negative tumours. Trastuzumab is a selective treatment targeting the HER2 pathway. Although the results on ef
- Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults
Cochrane Systematic Reviews, 29-Aug-2014
Kaposi's sarcoma remains the most common cancer in Sub-Saharan Africa and the second most common cancer in HIV-infected patients worldwide. Since the introduction of highly active antiretroviral therapy (HAART), there has been a decline in its incidence.
- Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer
Cochrane Systematic Reviews, 11-Feb-2015
Ovarian cancer is the sixth most common cancer among women and the leading cause of death in women with gynaecological malignancies. Opinions differ regarding the role of ultra-radical (extensive) cytoreductive surgery in ovarian cancer treatment.
